NeOnc Technologies (NTHI)
Develops intranasal NEO100 and oral NEO212 candidates for brain tumors.
$4.96
At close+0.23 (+4.86%)
Something off on this page? Send us feedback.
Next report
Nov 12, 2026
estimated · in 70 days
EPS estimate
−$0.23
Revenue estimate
—
Fiscal quarter
Q3 FY26
EPSReportedEstimate
——Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported——−$0.45−$0.40−$0.38−$0.58−$0.58Pending
Estimate——−$0.37−$0.37−$0.22−$0.12−$0.12−$0.23
Surprise——−21.6%−7.3%−73.5%−397.1%−397.1%—
RevenueReportedEstimate
——Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported———————Pending
Estimate————————
Surprise————————
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.23 | — | — |
| Aug 2026 | −$0.12 | −$0.58 | −397.1% |
| Aug 2026 | −$0.12 | −$0.58 | −397.1% |
| May 2026 | −$0.22 | −$0.38 | −73.5% |
| Mar 2026 | −$0.37 | −$0.40 | −7.3% |
The latest year is open to everyone — the 1 quarter behind it read with an account. Sign in | |||
| Nov 2025 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | −$0.23 | — | — | — | — | — | — |
| Aug 14, 2026 | −$0.12 | −$0.58 | −397.1% | — | — | — | −20.5% |
| Aug 10, 2026 | −$0.12 | −$0.58 | −397.1% | — | — | — | 0.0% |
| May 18, 2026 | −$0.22 | −$0.38 | −73.5% | — | — | — | +2.6% |
| Mar 31, 2026 | −$0.37 | −$0.40 | −7.3% | — | — | — | −13.1% |
The latest year is open to everyone — the 1 quarter behind it read with an account. Sign in | |||||||
| Nov 14, 2025 | |||||||